Ascendis Pharma (ASND) plans to list its ordinary shares directly on Nasdaq, effective at the opening of trading on April 20. As part of the transition to a direct listing of ordinary shares on The Nasdaq Global Select Market, all outstanding ADSs will be exchanged for ordinary shares. Each ADS currently eligible for trading will be exchanged for one ordinary share, which will be listed and commence trading on The Nasdaq Global Select Market under the Company’s existing ticker symbol “ASND” on April 20.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma announces new data from COACH trial
- Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia
- Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.
- Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises
- Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM